An
CD133 (prominin-1)
Cancer stem cells
In-silico analysis
third extracellular domain (D-EC3)
Journal
Iranian journal of pharmaceutical research : IJPR
ISSN: 1735-0328
Titre abrégé: Iran J Pharm Res
Pays: Netherlands
ID NLM: 101208407
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
23
2
2022
pubmed:
24
2
2022
medline:
24
2
2022
Statut:
ppublish
Résumé
The selection of the appropriate fragment of the cell surface receptors as an antigen is significant for the production of antibodies. CD133, as a suitable biomarker candidate in the cancer stem cells (CSCs), is a glycosylated protein. The antibodies used for analyzing it recognize glycosylated epitopes of CD133. Since the glycosylated motifs have a dynamic nature over the lifetime of a protein, they limit the detection of CD133. In this study, to access a specific antibody against the antigenic, accessible, and non-glycosylated fragment of the native CD133, we performed an
Identifiants
pubmed: 35194430
doi: 10.22037/ijpr.2021.115662.15470
pmc: PMC8842621
doi:
Types de publication
Journal Article
Langues
eng
Pagination
80-91Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Oncotarget. 2017 Sep 8;8(43):75756-75766
pubmed: 29088907
Life Sci. 2017 Sep 1;184:25-29
pubmed: 28697984
Nat Methods. 2015 Jan;12(1):7-8
pubmed: 25549265
Life Sci. 2021 Jan 15;265:118791
pubmed: 33220288
J Drug Target. 2019 Mar;27(3):257-269
pubmed: 29911902
PLoS One. 2016 Oct 4;11(10):e0164079
pubmed: 27701459
Oncol Lett. 2016 Nov;12(5):3059-3065
pubmed: 27899964
J Mol Med (Berl). 2008 Sep;86(9):1025-32
pubmed: 18535813
BMC Bioinformatics. 2008 Dec 02;9:514
pubmed: 19055730
Breast Cancer Res Treat. 2020 Jan;179(1):241-249
pubmed: 31571071
Exp Hematol Oncol. 2013 Jul 01;2(1):17
pubmed: 23815814
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Toxins (Basel). 2016 May 28;8(6):
pubmed: 27240402
Infect Immun. 2004 Oct;72(10):5775-82
pubmed: 15385477
Front Microbiol. 2014 Apr 17;5:172
pubmed: 24860555
Expert Opin Ther Targets. 2010 Jun;14(6):621-32
pubmed: 20426697
Cancer Res. 2010 Jan 15;70(2):719-29
pubmed: 20068153
Clin Transl Med. 2018 Jul 9;7(1):18
pubmed: 29984391
BMC Bioinformatics. 2007 Jan 05;8:4
pubmed: 17207271
Iran J Microbiol. 2016 Feb;8(1):29-35
pubmed: 27092222
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8
pubmed: 12824418
J Med Microbiol. 2018 Jun;67(6):820-827
pubmed: 29737965
PLoS One. 2015 Jun 18;10(6):e0130519
pubmed: 26086074
Protein Expr Purif. 1996 Mar;7(2):129-36
pubmed: 8812844
Curr Pharm Biotechnol. 2021 Aug 09;:
pubmed: 34375187
J Immunol Methods. 2010 Sep 30;361(1-2):110-5
pubmed: 20674577
J Mol Biol. 1996 Nov 22;264(1):121-36
pubmed: 8950272
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W72-6
pubmed: 15980571
Oncol Lett. 2018 Jul;16(1):431-438
pubmed: 29928431
Iran Biomed J. 2010 Jul;14(3):97-102
pubmed: 21079660
Oncol Lett. 2015 Jun;9(6):2603-2608
pubmed: 26137114
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W407-10
pubmed: 17517781
Glycoconj J. 2017 Aug;34(4):441-452
pubmed: 28624993
Front Oncol. 2020 Apr 23;10:582
pubmed: 32391268
Mol Immunol. 2019 Jul;111:128-135
pubmed: 31054406
BMB Rep. 2017 Jun;50(6):285-298
pubmed: 28270302